Weekly Recap | Upstream Bio -0.72%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Upstream Bio (UPB) fell 0.72% this week to close at $2.74, underperforming the S&P 500, which slipped 0.47%. After a pre-market pop of over 11% on Monday, the stock failed to hold the move, trading between $2.75 and $3.09 through Wednesday before closing at $2.99 on Thursday and then dropping nearly 10% intraday on Friday to a range low of $2.695. There was no major catalyst this week; the 14.31% amplitude points to a tape-driven session.
The Week
Upstream Bio (UPB) fell 0.72% this week to close at $2.74, underperforming the S&P 500, which slipped 0.47%. After a pre-market pop of over 11% on Monday, the stock failed to hold the move, trading between $2.75 and $3.09 through Wednesday before closing at $2.99 on Thursday and then dropping nearly 10% intraday on Friday to a range low of $2.695. There was no major catalyst this week; the 14.31% amplitude points to a tape-driven session.
Analyst Ratings
Seven brokers cover the name: four rate it strong buy, one buy, and two hold, with no under or sell ratings. The consensus rating is buy, with a consensus target of $29.83, about 988.8% above spot. Targets range from $9.00 to $75.00, so dispersion is wide. The stock ranks 221st out of 511 biotech names by analyst rating.
The Week Ahead
Monday brings the US Dallas Fed manufacturing business activity index, followed on Tuesday by durable goods orders, FHFA house prices, the Case Shiller 20-city index, new home sales, the Richmond Fed composite index and consumer confidence. Whether Friday’s intraday record low is absorbed will be an early read on sentiment repair.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.